文献速递产科母胎医学

妊娠期糖尿病患者每日与隔日血糖监测的新生儿出生体重比较:一项随机对照试验

Neonatal Birth Weight With Daily Compared With Every-Other-Day Glucose Monitoring in Gestational Diabetes Mellitus: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2024-02-08

在纽约市一家医院开展的非劣效性随机对照试验,纳入197例妊娠20周后诊断妊娠期糖尿病且已每日监测血糖至少7天的单胎孕妇,随机分为每日监测组(98例)与隔日监测组(99例)。隔日监测组新生儿平均出生体重3,181±482 g,每日监测组为3,090±418 g,平均差值上限197 g低于预设非劣效界值200 g(P=.046)。两组用药、血糖控制及满意度无显著差异,隔日监测组治疗依从性更高。

要点

  • 隔日血糖监测在新生儿出生体重方面非劣效于每日监测,平均差值上限197 g低于200 g界值。
  • 两组需要药物治疗的患者数、启动孕周及药物类型均无显著差异。
  • 隔日监测组治疗依从性更高,但患者满意度无差异。

核心结论

  • 在妊娠期糖尿病患者中,隔日监测血糖与每日监测同样有效,对出生体重、用药启动或血糖控制无显著影响。
  • 降低血糖监测频率可能有助于减轻妊娠期糖尿病患者的情绪、身体和经济负担。

研究设计与样本

  • 非劣效性随机对照试验,在纽约市一家医院于2021年4月至2022年5月开展。
  • 纳入妊娠20周后诊断妊娠期糖尿病、既往每日血糖监测至少7天的单胎妊娠患者,随机分为每日监测组(98例)与隔日监测组(99例),共197例。
  • 主要结局为新生儿出生体重,预设非劣效界值为200 g(80%把握度,单侧α=0.05),计算所需总样本量为196例。

主要发现

  • 新生儿平均出生体重每日监测组为3,090±418 g,隔日监测组为3,181±482 g。
  • 主要结局平均差值上限为197 g,低于非劣效界值200 g(P=.046)。
  • 随机化后需要药物治疗的患者数、启动药物治疗的孕周及药物类型均无显著差异。
  • 两组平均空腹和餐后血糖值相似。
  • 隔日监测组治疗依从性增加,但患者满意度无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether universal use of every-other-day glucose monitoring in patients with gestational diabetes mellitus (GDM) resulted in similar birth weights and medication use and was preferred by the patient compared with traditional daily glucose monitoring. METHODS: This was a noninferiority randomized controlled trial conducted at a single New York City hospital between April 2021 and May 2022. Patients with singleton pregnancies who were diagnosed with GDM after 20 weeks of gestation and had a minimum of 7 days of previous daily blood glucose testing were randomly assigned to test blood glucose values daily or every other day. The primary outcome was neonatal birth weight. We calculated a total sample size of 196 participants needed for noninferiority to be tested, assuming the mean birth weight in the every-other-day group, compared with the daily group, was no higher than the predefined noninferiority margin of 200 g (80% power and one-sided alpha of 0.05). Postrandomization characteristics, including blood glucose values and medication initiation and timing, were recorded. Satisfaction with treatment group was assessed using the validated Oxford Maternity Diabetes Treatment Satisfaction Questionnaire. RESULTS: A total of 197 patients were randomized: 98 in the daily group and 99 in the every-other-day group. Baseline characteristics were similar between groups. The mean neonatal birth weight was similar between groups (mean±SD 3,090±418 g among newborns in the daily group compared with 3,181±482 g among newborns in the every-other-day group). For the primary outcome, the every-other-day group was found to be noninferior to the daily group with an upper confidence limit for the mean difference in mean birth weight of 197 g, which was below the noninferiority margin of 200 g ( P =.046). Postrandomization, there were no significant differences in the number of patients who required medication, the gestational age at which medication was started, or the type of medication used. Average fasting and postprandial glucose values were similar between groups. There was an increase in adherence to treatment group in those randomized to every-other-day blood sugars, but no difference in patient satisfaction. CONCLUSION: In patients with GDM, testing blood glucose values every other day was as effective as testing daily, without apparent effects on birth weight, medication initiation, or glucose control. Reduced frequency of blood glucose monitoring might help decrease the emotional, physical, and financial burden experienced by patients with GDM. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04857073.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Feldman KM, Coughlin A, Feliciano J, et al. Neonatal Birth Weight With Daily Compared With Every-Other-Day Glucose Monitoring in Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstet Gynecol. 2024. PMID: 38330409. doi:10.1097/AOG.0000000000005528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。